Corinne Jenkins
Stock Analyst at Goldman Sachs
(1.66)
# 3,419
Out of 5,090 analysts
60
Total ratings
43.9%
Success rate
-5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IDYA IDEAYA Biosciences | Maintains: Neutral | $27 → $30 | $35.53 | -15.56% | 6 | Oct 21, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $157 → $139 | $105.20 | +32.13% | 10 | Oct 17, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $20 → $24 | $21.01 | +14.26% | 6 | Sep 18, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.30 | -22.78% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $31.38 | -29.89% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $9.27 | +61.81% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $5.22 | +149.28% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $38.61 | -27.48% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $2.06 | +3,006.80% | 6 | Aug 15, 2023 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $216 → $184 | $34.10 | +439.59% | 2 | Mar 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $21 | $2.91 | +622.89% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $28.92 | -51.59% | 2 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $160 | $3.90 | +4,002.56% | 2 | Dec 15, 2021 |
IDEAYA Biosciences
Oct 21, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $35.53
Upside: -15.56%
Rhythm Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $157 → $139
Current: $105.20
Upside: +32.13%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $20 → $24
Current: $21.01
Upside: +14.26%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.30
Upside: -22.78%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $31.38
Upside: -29.89%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $9.27
Upside: +61.81%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $5.22
Upside: +149.28%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $38.61
Upside: -27.48%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $2.06
Upside: +3,006.80%
RAPT Therapeutics
Mar 15, 2023
Maintains: Buy
Price Target: $216 → $184
Current: $34.10
Upside: +439.59%
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $2.91
Upside: +622.89%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $28.92
Upside: -51.59%
Dec 15, 2021
Initiates: Neutral
Price Target: $160
Current: $3.90
Upside: +4,002.56%